In today’s episode we are joined by Kirsty Wirth to discuss the latest developments in gut microbiome testing, including the shift from culturing to metagenomic testing, and the significance of TGA approval for these tests. We explore the importance of using meaningful diagnostic markers, such as calprotectin, to inform treatment decisions and bridge the gap between holistic and Western practitioners, the ability to receive care through Medicare without additional costs, the potential for multiple modalities to work together for optimal patient care, the importance of understanding the relationship between gut health and stress and so much more.   Head to https://www.stephlowe.com/podcasts/494 for show notes, episode transcripts and more.